The treatment notably reduces the expression of pro-inflammatory cytokines and key enzymes such as COX-2 and iNOS, contributing to the alleviation of oxidative stress and inflammation in colonic tissues, which are crucial factors in the pathogenesis of IBD. This evidence concerns the gene NOS2 and inflammatory bowel disease.